Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 07/31/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.    Case No. 18-10518 (KG)
Debtor    Reporting Period: June 1, 2018 - June 30, 2018

MOR - 2

Statement of Operations

For the Period: June 1, 2018 - June 30, 2018

(Unaudited)

 

$ USD ‘000s

   June 1, 2018 - June 30, 2018     March 12 - June 30, 2018  

Net product sales

   $ 4,815     $ 24,977  

Cost of product sales

     (1,142     (5,607

Operating expenses:

    

Research and development

     (554     (2,367

Selling, general and administrative

     (4,177     (28,822

Amortization expense of intangible assets

     (661     (2,411
  

 

 

   

 

 

 

Total operating expenses

     (5,392     (33,600
  

 

 

   

 

 

 

Loss from operations

     (1,719     (14,230

Other income/(expense):

    

Interest income

     148       542  

Refundable tax credit(2)

     —         1,300  

Interest expense

     (147     (600
  

 

 

   

 

 

 

Total other income (expenses)

     0       1,242  
  

 

 

   

 

 

 

Net loss

     (1,719     (12,988

Reorganization expenses (1)

     (3,751     (178,290
  

 

 

   

 

 

 

Net loss

   $ (5,470   $ (191,278
  

 

 

   

 

 

 

Notes:

 

(1)

Reorganization expenses includes the write up of the notes to the principle balance and the elimination of the debt discount and debt costs related to the 2013 debt.

(2)

Refundable tax credit includes refundable alternative minimum tax as created by the Tax Cuts and Jobs Act.